+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Metastatic Prostate Cancer Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027

  • Report

  • 100 Pages
  • February 2022
  • Region: Global
  • Infinium Global Research
  • ID: 5557582
The report on the global metastatic prostate cancer market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global metastatic prostate cancer market to grow with a CAGR of around 8% over the forecast period from 2021-2027. The study on metastatic prostate cancer market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on metastatic prostate cancer market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global metastatic prostate cancer market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global metastatic prostate cancer market over the period of 2019 to 2027. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings


1) Drivers

  • An increase in the investment in research for the development of therapeutic products to treat these tumors, innovative technologies in screening and diagnostics testing are expected to boost the market growth in the upcoming years

2) Restraints

  • Owing to various side effects of the treatment, high cost for the treatment, and poor reimbursement policies costs, the expensive nature of combination therapies will hamper the market growth

3) Opportunities

  • The launch of new effective products and improved R&D investment by drug innovators will provide market growth opportunities to grow in the forthcoming years.

Research Methodology


A) Primary Research


Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

B) Secondary Research


Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global metastatic prostate cancer market is segmented on the basis of drug type, and distribution channel.

The Global Metastatic Prostate Cancer Market by Drug Type

  • Biological Therapy
  • Chemotherapy
  • Hormone Therapy
  • Others

The Global Metastatic Prostate Cancer Market by Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Company Profiles


The companies covered in the report include
  • AstraZeneca plc
  • Novartis
  • SeleXel
  • Telix Pharmaceuticals
  • Zenith Epigenetics Ltd
  • Genentech
  • Sanofi
  • Bayer AG
  • Astellas Pharma
  • GlaxoSmithKline Plc

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the metastatic prostate cancer market.
2. Complete coverage of all the segments in the metastatic prostate cancer market to analyze the trends, developments in the global market and forecast of market size up to 2027.
3. Comprehensive analysis of the companies operating in the global metastatic prostate cancer market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Metastatic Prostate Cancer Market Highlights
2.2. Metastatic Prostate Cancer Market Projection
2.3. Metastatic Prostate Cancer Market Regional Highlights
3. Global Metastatic Prostate Cancer Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Analysis of COVID-19 impact on the Metastatic Prostate Cancer Market
3.4. Porter's Five Forces Analysis
3.5. Growth Matrix Analysis
3.5.1. Growth Matrix Analysis by Drug Type
3.5.2. Growth Matrix Analysis by Distribution Channel
3.5.3. Growth Matrix Analysis by Region
3.6. Value Chain Analysis of Metastatic Prostate Cancer Market
4. Metastatic Prostate Cancer Market Macro Indicator Analysis
5. Global Metastatic Prostate Cancer Market by Drug Type
5.1. Biological Therapy
5.2. Chemotherapy
5.3. Hormone Therapy
5.4. Others
6. Global Metastatic Prostate Cancer Market by Distribution Channel
6.1. Hospital Pharmacies
6.2. Drug Stores
6.3. Retail Pharmacies
6.4. Online Pharmacies
7. Global Metastatic Prostate Cancer Market by Region 2021-2027
7.1. North America
7.1.1. North America Metastatic Prostate Cancer Market by Drug Type
7.1.2. North America Metastatic Prostate Cancer Market by Distribution Channel
7.1.3. North America Metastatic Prostate Cancer Market by Country
7.2. Europe
7.2.1. Europe Metastatic Prostate Cancer Market by Drug Type
7.2.2. Europe Metastatic Prostate Cancer Market by Distribution Channel
7.2.3. Europe Metastatic Prostate Cancer Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Metastatic Prostate Cancer Market by Drug Type
7.3.2. Asia-Pacific Metastatic Prostate Cancer Market by Distribution Channel
7.3.3. Asia-Pacific Metastatic Prostate Cancer Market by Country
7.4. RoW
7.4.1. RoW Metastatic Prostate Cancer Market by Drug Type
7.4.2. RoW Metastatic Prostate Cancer Market by Distribution Channel
7.4.3. RoW Metastatic Prostate Cancer Market by Sub-region
8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Metastatic Prostate Cancer Market
8.2. Companies Profiled
8.2.1. AstraZeneca plc
8.2.2. Novartis
8.2.3. SeleXel
8.2.4. Telix Pharmaceuticals
8.2.5. Zenith Epigenetics Ltd
8.2.6. Genentech
8.2.7. Sanofi
8.2.8. Bayer AG
8.2.9. Astellas Pharma
8.2.10. GlaxoSmithKline Plc

Companies Mentioned

  • AstraZeneca plc
  • Novartis
  • SeleXel
  • Telix Pharmaceuticals
  • Zenith Epigenetics Ltd
  • Genentech
  • Sanofi
  • Bayer AG
  • Astellas Pharma
  • GlaxoSmithKline Plc